PDCD1 and neoplasm: Therapeutic potential of a systemically delivered VSV encoding tumor antigens c-Myc, HIF-2α, and Sox-10 in combination with anti-PD-1 or anti-CTLA-4 therapy has been shown in a pre-clinical glioma model [104].